The Experience Exchange
The Experience Exchange is an open-format, interactive meeting place designed to foster the exchange of groundbreaking scientific information through non-ce educational programming and networking opportunities.
This dynamic space allows attendees to easily navigate the space and receive additional one-on-one time with speakers, exhibitors, and other pain science professionals.
What to Expect
Learning
Extended Poster Viewing allows all posters in one place at one time. A list of accepted posters will be available soon.
The Learning Lounge, an innovative, interactive theater were both industry and association driven content can be delivered. The Learning Lounge is the 'hub' of the Experience Exchange. The Learning Lounge will host Town Hall Talks and Session Sound Bytes.
Town Hall Talks will showcase products, services, and programs, relevant to your profession. Topics can range from risk evaluation and mitigation strategies (REMS), compliance, patient safety, diversion, and research.
Town Hall Talks
Wednesday, May 11
5:15-5:45 pm supported by Collegium Pharmaceuticals
Insights on Novel Technology in Pain Management With Abuse-Deterrent Extended-Release Opioids
Jeffrey Gudin, MD
Thursday, May 12
9:45-10:45 am supported by Teva
Putting Patients First: Developing Abuse-Deterrent Opioids
Jeffrey Gudin, MD
This program examines the FDA guidance on how Industry can evaluate abuse-deterrent opioid formulations, as part of a multifaceted approach, in helping to address opioid abuse, misuse and diversion.
1-2 pm supported by Teva
Update on Abuse Deterrence
Michael Brennan, MD
Healthcare professionals (HCPs) who treat moderate-to-severe chronic pain are often faced with balancing the need for adequate pain control on one side and the individual and societal risks of prescription opioid abuse. This program will outline how a multifaceted approach may help address opioid abuse. Specifically, we will review the FDA Guidance on abuse-deterrent opioid formulations, outline some of the approaches to potentially provide a barrier to abuse, and discuss how they may be tested to demonstrate abuse-deterrence.
3:55-4:25 pm supported by Cara Therapeutics
Moving Beyond Mu with Kappa Opioid Receptor Agonists: Leaving the Baggage Behind
Joseph Stauffer, DO, MBA; Jeffrey A. Gudin, MD
Learn about a novel peripherally acting kappa opioid receptor agonist, CR845, which is in phase 3 trials for postoperative pain (IV) and phase 2 trials for chronic pain (oral). Its unique pharmacologic properties produce analgesia with low abuse potential and little-to-no mu opioid side effects like nausea/vomiting and respiratory depression. Click here to register.
4:35-5:05 pm supported by Depomed
Next Generation Analgesia: The First and Only FDA-Approved Long-Acting Opioid Designed to Control Both Nociceptive Pain and the Neuropathic Pain Associated with Diabetic Peripheral Neuropathy
Speaker:Matthew Kaplan, DO
The complexities of chronic pain management require clinicians to evaluate a variety of clinical issues and solutions. Studies suggest chronic low back pain may have components of nociceptive and neuropathic pain. In and epidemiology study (N=85,014), 44% of patients suffered from a mix of neuropathic and nociceptive pain. Come hear about the first and only FDA-approved long-acting opioid designed to control both nociceptive pain and the neuropathic pain associated with diabetic peripheral neuropathy.
Friday, May 13
Join us for informal, TED-style talks in which you'll have an opportunity to interact with speakers on clinical and basic science topics.
8:45-9:05 am
Time to Abandon Pain Intensity as Our Primary Measure of Chronic Pain?
Mark Sullivan, MD PhD; Jane Ballantyne, MD
DESCRIPTION TBD
9:10-9:30 am
Emeran Mayer, MD
TITLE AND DESCRIPTION TBD
9:35-9:55 am
Sean Mackey, MD PhD
TITLE AND DESCRIPTION TBD
10-10:20 am
Howard Fields, MD PhD
TITLE AND DESCRIPTION TBD
Town Hall Talks
12:10-12:40 pm supported by Cara Therapeutics
Moving Beyond Mu with Kappa Opioid Receptor Agonists: Leaving the Baggage Behind
Joseph Stauffer, DO, MBA; Jeffrey A. Gudin, MD
Learn about a novel peripherally acting kappa opioid receptor agonist, CR845, which is in phase 3 trials for postoperative pain (IV) and phase 2 trials for chronic pain (oral). Its unique pharmacologic properties produce analgesia with low abuse potential and little-to-no mu opioid side effects like nausea/vomiting and respiratory depression. Click here to register.
12:50-1:20 pm supported by Recro Pharmaceuticals
Can We Meet the Opioid-Free Challenge?
Speaker: Eugene R. Viscusi, MD
The goals of perioperative pain management are to relieve suffering, achieve early mobilization after surgery, reduce length of hospital stay, and achieve patient satisfaction. Opioids are often the cornerstone of perioperative pain control, as they provide swift and potent analgesia when administered parenterally, but all opioids share common side effects. The purpose of this presentation is to explore opioid-sparing modalities, and if and how they may contribute to opioid-free pain management and concerns that such an approach may engender.
Networking
Connection Centrals networking areas will be set-up in the Experience Exchange to meet and interact with other attendees. These designated areas great for those one-on-one meetings or for a casual discussion.
Navigating
A new design layout to enhance collaboration.
Explore the Floor is an unique way for attendees to navigate the Experience Exchange. This new interactive experience allows attendees and exhibitors to discuss products and services that will benefit the pain science profession. Attendees will receive an explorer card to be stamped at select booths. Once the card is filled, enter the card into this year's prize drawing.